Search hospitals > Georgia > Atlanta

Emory University Hospital/Winship Cancer Institute

Claim this profile
Atlanta, Georgia 30322
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Multiple Myeloma
Conducts research for Pancreatic Cancer
1082 reported clinical trials
100 medical researchers
Photo of Emory University Hospital/Winship Cancer Institute in AtlantaPhoto of Emory University Hospital/Winship Cancer Institute in AtlantaPhoto of Emory University Hospital/Winship Cancer Institute in Atlanta

Summary

Emory University Hospital/Winship Cancer Institute is a medical facility located in Atlanta, Georgia. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Multiple Myeloma, Pancreatic Cancer and other specialties. Emory University Hospital/Winship Cancer Institute is involved with conducting 1,082 clinical trials across 815 conditions. There are 100 research doctors associated with this hospital, such as Jonathan Cohen, MD, Conor Steuer, Ticiana A. Leal, and Olatunji Alese.

Area of expertise

1Cancer
Global Leader
Emory University Hospital/Winship Cancer Institute has run 160 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Breast Cancer
Global Leader
Emory University Hospital/Winship Cancer Institute has run 141 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
HER2 negative
Stage III

Top PIs

Clinical Trials running at Emory University Hospital/Winship Cancer Institute

Lung Cancer
Breast Cancer
Skin Cancer
Prostate Cancer
Multiple Myeloma
Breast cancer
Colorectal Cancer
Ovarian Cancer
Cancer
Brain Tumor
Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Image of trial facility.

Radiation Therapy

for Brain Metastasis

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain.
Recruiting2 awards Phase 312 criteria
Image of trial facility.

Osimertinib + Bevacizumab

for Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Emory University Hospital/Winship Cancer Institute?
Where is Emory University Hospital/Winship Cancer Institute located?
Who should I call to ask about financial aid or insurance network?
What insurance does Emory University Hospital/Winship Cancer Institute accept?
What awards or recognition has Emory University Hospital/Winship Cancer Institute received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security